Avenue Therapeutics Shares Are Trading Lower. The Company Recently Announced a 1-for-75 Reverse Stock Split of Its Common Stock.
Avenue Therapeutics Shares Are Trading Lower. The Company Recently Announced a 1-for-75 Reverse Stock Split of Its Common Stock.
Why Aon Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Aon plc (NYSE:AON) fell sharply during Friday's session after the company reported worse-than-expected quarterly financial results.Aon posted adjusted earnings of $5.66 per share, missing ma
Avenue Therapeutics To Carry Out 1-for-75 Reverse Stock Split On April 26th, 2024
April 25th - $Avenue Therapeutics(ATXI.US)$ is about to implement a 1-for-75 reverse stock split of shares. The shares will begin trading on a split-adjusted basis from April 26th, 2024.$Avenue Therap
Crude Oil Moves Lower; B. Riley Financial Shares Jump
U.S. stocks traded slightly lower toward the end of trading, with the S&P 500 edging lower on Wednesday.The Dow traded down 0.18% to 38,434.99 while the NASDAQ fell 0.09% to 15,682.38. The S&P 500 als
Why Teledyne Technologies Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Teledyne Technologies Incorporated (NYSE:TDY) fell sharply during Wednesday's session after the company reported worse-than-expected first-quarter financial results and cut FY24 adjusted EPS
Dow Dips Over 100 Points; Ribbon Communications Shares Spike Higher
U.S. stocks traded mixed midway through trading, with the Dow Jones falling over 100 points on Wednesday.
Why Avenue Therapeutics (ATXI) Shares Are Getting Hammered
Avenue Therapeutics Inc (NASDAQ:ATXI) shares are trading lower by 28.5% to $0.09 during Wednesday's session after the company announced a reverse stock split.The company is implementing a 1-for-75 rev
Nasdaq Rises 0.5%; Tesla Shares Jump After Q1 Results
U.S. stocks traded mixed this morning, with the Nasdaq Composite gaining around 0.5% on Wednesday.Following the market opening Wednesday, the Dow traded down 0.10% to 38,465.33 while the NASDAQ rose 0
Avenue Therapeutics Shares Are Trading Lower After the Company Announced a Reverse Stock Split.
Avenue Therapeutics Shares Are Trading Lower After the Company Announced a Reverse Stock Split.
Avenue Therapeutics Will Effect a 1-For-75 Reverse Split >ATXI
Avenue Therapeutics Will Effect a 1-For-75 Reverse Split >ATXI
Avenue Therapeutics: Reverse Split to Bring Co Into Compliance With Nasdaq's $1.00 Per Shr Minimum Bid Price Requirement >ATXI
Avenue Therapeutics: Reverse Split to Bring Co Into Compliance With Nasdaq's $1.00 Per Shr Minimum Bid Price Requirement >ATXI
12 Health Care Stocks Moving In Tuesday's After-Market Session
GainersJaguar Health (NASDAQ:JAGX) shares rose 25.3% to $0.11 during Tuesday's after-market session. The company's market cap stands at $31.1 million. aTyr Pharma (NASDAQ:LIFE) shares rose 10.45% to $
Avenue Therapeutics' AJ201: A Buy Rating for Innovative SBMA Treatment and Promising Clinical Progress
Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024
MIAMI, March 25, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of therapies for the
Navigating the Maze: Avenue Therapeutics Grapples With Regulatory Hurdles for IV Tramadol
Avenue Therapeutics Q4 EPS $(0.98) Misses $(0.10) Estimate
Avenue Therapeutics (NASDAQ:ATXI) reported quarterly losses of $(0.98) per share which missed the analyst consensus estimate of $(0.10) by 880 percent. This is a 20.33 percent increase over losses of
Avenue Therapeutics 2023 Loss/Shr 98c >ATXI
Avenue Therapeutics 2023 Loss/Shr 98c >ATXI
Avenue Therapeutics: Nasdaq Granted Extension for Compliance to Continued Listing Through May 20 >ATXI
Avenue Therapeutics: Nasdaq Granted Extension for Compliance to Continued Listing Through May 20 >ATXI
Avenue Therapeutics: Final Agreement Reached With FDA on Study Design and Analysis Approach for Phase 3 Safety Study of IV Tramadol >ATXI
Avenue Therapeutics: Final Agreement Reached With FDA on Study Design and Analysis Approach for Phase 3 Safety Study of IV Tramadol >ATXI
Press Release: Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights
Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights - Enrollment completed in Phase 1b/2a clinical trial of AJ201 for spinal and bulbar muscular atrophy; topl
No Data